146 related articles for article (PubMed ID: 30122017)
1. [The value of platelet count in predicting the efficacy of rituximab treatment in adult patients with chronic primary immune thrombocytopenia].
Wang SX; Nie YB; Ju MK; Sun T; Li HY; Zhang DL; Zhang L; Yang RC
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):573-578. PubMed ID: 30122017
[No Abstract] [Full Text] [Related]
2. [Influencing Factors on Prognosis of Adult Patients with Chronic Primary ITP Treated with Rituximab and Predictive Value of Platelet Count].
Hu LN; Liu Y; Liu YL; Dan G
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1332-1337. PubMed ID: 32798422
[TBL] [Abstract][Full Text] [Related]
3. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
4. [A multicenter clinical trial of caffeic acid tablet in treatment of 103 primary immune thrombocytopenia patients].
Qin P; Wei Y; Hou M; Zhao C; Shen Z
Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):103-6. PubMed ID: 25778883
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
[TBL] [Abstract][Full Text] [Related]
6. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
Li Y; Wang XM; Mao M; Zhang XY; Fu L; Ai HM; Zhang LX
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of rhTPO in the treatment of pediatric primary immune thrombocytopenia].
Huang Y; Liu X; Xue F; Chen Y; Liu W; Fu R; Zhang L; Yang R
Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):511-4. PubMed ID: 26134019
[TBL] [Abstract][Full Text] [Related]
8. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
[TBL] [Abstract][Full Text] [Related]
9. Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.
Hindilerden F; Yönal-Hindilerden İ; Yenerel MN; Nalçacı M; Diz-Küçükkaya R
Turk J Haematol; 2017 Mar; 34(1):72-80. PubMed ID: 27102929
[TBL] [Abstract][Full Text] [Related]
10. [Clinical analysis of lower doses rituximab for children primary immune thrombocytopenia].
Liu X; Huang Y; Chen Y; Liu W; Xue F; Zhang L; Yang R
Zhonghua Xue Ye Xue Za Zhi; 2014 Dec; 35(12):1079-82. PubMed ID: 25543701
[TBL] [Abstract][Full Text] [Related]
11. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
[TBL] [Abstract][Full Text] [Related]
12. The impact of Fc gamma receptor IIa and IIIa gene polymorphisms on the therapeutic response of rituximab in Egyptian adult immune thrombocytopenic purpura.
Ellithy HN; Ahmed SH; Shahin GH; Matter MM; Talatt M
Hematology; 2018 Apr; 23(3):169-174. PubMed ID: 28856973
[TBL] [Abstract][Full Text] [Related]
13. [A clinical comparative study on treatment of severe newly diagnosed immune thrombocytopenia by recombinant human thrombopoietin combined with glucocorticoid].
Gu SY; Zhuang JL; Zou SH; Li F; Wang ZM; Cheng YF; Wang WG; Cheng ZX; Yuan L; Cheng LY; Wei Z
Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):883-6. PubMed ID: 24171964
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab.
Gokcebay DG; Tavil B; Fettah A; Yarali N; Azik FM; Tunc B
Clin Appl Thromb Hemost; 2013; 19(6):663-7. PubMed ID: 22815318
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
16. [Clinical analysis of recombinant human thrombopoietin for 92 adults with severe primary immune thrombocytopenia].
Liu X; Huang Y; Liu W; Chen Y; Xue F; Zhang L; Yang R
Zhonghua Xue Ye Xue Za Zhi; 2015 Apr; 36(4):312-5. PubMed ID: 25916293
[TBL] [Abstract][Full Text] [Related]
17. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for children with immune thrombocytopenia: a systematic review.
Liang Y; Zhang L; Gao J; Hu D; Ai Y
PLoS One; 2012; 7(5):e36698. PubMed ID: 22666325
[TBL] [Abstract][Full Text] [Related]
19. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J;
Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T
BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
